Reduced Cancer Drug Reimbursements Don’t Impede Access – JAMA Study
This article was originally published in The Pink Sheet Daily
2003-2006 Medicare claim review finds no evidence that lowering physician payments adversely affected access to care.
You may also be interested in...
The Medicare program is earmarking $300 mil. for a "quality of care" demonstration project that should help smooth the transition to ASP-based reimbursement in 2005
HIV community is pushing back against the change, arguing that revenue lost from reduced reimbursement will cripple providers, which use the extra funds for wrap-around patient support and services.
As MACPAC moves toward formal recommendations, a CBO analysis finds that differential Medicaid rebates for drugs approved through the accelerated pathway could save the federal government up to $1bn over five years.